Giuseppe Rossi
A5101631020- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Acute Lymphoblastic Leukemia research
- Viral-associated cancers and disorders
- Multiple Myeloma Research and Treatments
- CNS Lymphoma Diagnosis and Treatment
- Neutropenia and Cancer Infections
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- CAR-T cell therapy research
- Fungal Infections and Studies
- Sarcoma Diagnosis and Treatment
- Hematopoietic Stem Cell Transplantation
- Antifungal resistance and susceptibility
- Cancer Treatment and Pharmacology
- Bone Tumor Diagnosis and Treatments
- Management of metastatic bone disease
- Eosinophilic Disorders and Syndromes
- Erythropoietin and Anemia Treatment
- Protein Degradation and Inhibitors
- Cutaneous lymphoproliferative disorders research
- Hematological disorders and diagnostics
- Retinoids in leukemia and cellular processes
- T-cell and Retrovirus Studies
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
2016-2025
Azienda Usl Toscana Centro
2024
Policlinico Umberto I
2024
University of Brescia
1998-2023
University of Siena
2023
University of Pisa
1987-2021
National Research Council
2010-2021
Fondazione Stella Maris
2021
Azienda Ospedaliera Universitaria Pisana
2021
Istituti di Ricovero e Cura a Carattere Scientifico
2011-2019
Abstract BACKGROUND: The authors set out to analyze if a simple comprehensive geriatric assessment (CGA) could objectively identify elderly patients with diffuse large cell lymphoma (DLCL) who can be effectively treated anthracycline‐containing immunochemotherapy. METHODS: CGA was performed in 84 consecutive DLCL aged >65 years and diagnosed at single institution. Treatment curative versus palliative intent chosen according clinical judgment. Cyclophosphamide, hydroxydaunomycin, Oncovin...
Short imatinib pulses were added to chemotherapy improve the long-term survival of adult patients with Philadelphia chromosome (Ph) -positive acute lymphoblastic leukemia (ALL), optimize complete remission (CR) and stem-cell transplantation (SCT) rates.Of 94 total (age range, 19 66 years), 35 represented control cohort (ie, imatinib-negative [IM-negative] group), 59 received 600 mg/d orally for 7 consecutive days imatinib-positive [IM-positive] starting from day 15 course 1 3 before during...
Chronic lymphocytic leukemia (CLL) is a disease of the elderly, characterized by immunodeficiency. Hence, patients with CLL might be considered more susceptible to severe complications from COVID-19. We undertook this retrospective international multicenter study characterize course COVID-19 in and identify potential predictors outcome. Of 190 confirmed diagnosed between 28/03/2020 22/05/2020, 151 (79%) presented (need oxygen and/or intensive care admission). Severe was associated advanced...
For patients with peripheral T-cell lymphoma (PTCL), outcomes using frontline treatment cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP-like therapy are typically poor. The ECHELON-2 study demonstrated that brentuximab vedotin plus (A+CHP) exhibited statistically superior progression-free survival (PFS) per independent central review improvements in overall versus CHOP for the of systemic anaplastic large cell other CD30-positive PTCL.
PURPOSE To evaluate the effect of bortezomib as induction therapy before autologous transplantation, followed by lenalidomide consolidation-maintenance in myeloma patients. PATIENTS AND METHODS Newly diagnosed patients age 65 to 75 years were eligible. Induction (bortezomib, doxorubicin, and dexamethasone [PAD]) included four 21-day cycles (1.3 mg/m(2) on days 1, 4, 8, 11), pegylated liposomal doxorubicin (30 day 4), (40 mg/d; cycle 1: 1 8 11, 15 18; 2 4: 4). Autologous transplantation was...
The optimal treatment of primary mediastinal large B-cell lymphoma (PMLBCL) is still undefined. In the absence randomised studies, we retrospectively analysed: (a) effectiveness two chemotherapy regimens (CHOP vs MACOP-B/VACOP-B) in complete remission (CR) achievement and event-free survival (EFS) (b) role involved-field radiotherapy (IF-RT) as consolidation. From 1982 to 1999, 138 consecutive patients affected by PMLBCL were treated 13 Italian institutions with CHOP (43) or MACOP-B/VACOP-B...
We performed a multicenter study to validate the concept that simple comprehensive geriatric assessment (CGA) can identify elderly, non-fit patients with diffuse large B-cell lymphoma (DLBCL) in whom curative treatment is not better then palliation, and analyze potential benefits of modulation after further subdividing category by CGA criteria. One hundred seventy-three aged > 69 treated or palliative intent clinical judgement only were grouped according into fit (46%), unfit (16%) frail...
Intra-articular injections of platelet-rich plasma (PRP) and hyaluronic acid (HA) represent efficacious medical treatments for osteoarthritis (OA), although no comparative study on long-term efficacy in hip OA exists. The goals the current were to compare clinical PRP vs HA at 12 months follow-up patients with evaluate influence type infiltration patient age, sex, body mass index, degree temporal evolution. One hundred chronic unilateral symptomatic consecutively enrolled randomly assigned 1...
Regular monitoring of bacterial epidemiology allows evaluation antibacterial strategies adopted. The aim this study was to disclose evolving trends in the infections and emerging antibiotic resistance unselected inpatients with haematological cancers. Febrile/infectious episodes occurring 823 patients consecutively admitted a single institution during 16 month period were analysed. Levofloxacin prophylaxis used >7 days expected neutropenia. Fever developed 364 (44.2%) an infection documented...
Purpose The clinical impact of positron emission tomography (PET) evaluation performed early during first-line therapy in patients with advanced-stage Hodgkin lymphoma, terms providing a rationale to shift who respond poorly onto more intensive regimen (PET response-adapted therapy), remains be confirmed. Patients and Methods phase II part the multicenter HD0801 study involved 519 de novo lymphoma received an initial treatment doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) underwent...